Financial Relationships With Ineligible Companies (Formerly Described as Commercial Interests by the ACCME) Within the Last 2 Years:
Douglas D. Richman, MD (Co-Chair)
Dr Richman has been a consultant to Antiva Biosciences, Gilead Sciences, Inc, and Merck and Co, Inc. (Updated 04/20/22)
Paul A. Volberding, MD (Co-Chair)
Dr Volberding has served on data and safety monitoring boards for Merck & Co, Inc. (Updated 04/20/22)
Roger J. Bedimo, MD, MS
Dr Bedimo has received research funding from ViiV Healthcare and Merck & Co. Inc, and serves on the Scientific Advisory Board for Merck & Co, Inc, ViiV Healthcare, Gilead Sciences, Inc, and Theratechnologies. (Updated 9/6/22)
Constance A. Benson, MD
Dr Benson has served on advisory and data safety monitoring boards for GlaxoSmithKline/ViiV Healthcare, received research grants awarded to her institution from Gilead Sciences, Inc., and serves as a consultant to NDA Partners, LLC. Her spouse has served as a consultant to CytoDyn, AbbVie and Sempra Energy; owns stock options in Antiva Biosciences and CytoDyn; has served on the board for Gilead Sciences, Inc., with payment remitted to his institution; and has served on data and safety monitoring boards for Gilead Sciences, Inc., and VIR. (Updated 04/20/22)
Judith S. Currier, MD
Dr Currier has served on the advisory board for Merck & Co, Inc. (Updated 04/20/22)
Carlos del Rio, MD
Dr Del Rio has served as a scientific advisor for Resverlogix. (Updated 05/23/22)
Ellen F. Eaton, MD
Dr Eaton has received grants paid to her institution from Bristol Myers Squibb, and has received consulting fees from Gilead Sciences, Inc. (Updated 12/14/22)
Rajesh T. Gandhi, MD
Dr Gandhi has no relevant financial affiliations to disclose. (Updated 12/08/22)
Donna M. Jacobsen, BS
Ms Jacobsen has no relevant financial affiliations to disclose. (Updated 04/20/22)
Raphael J. Landovitz, MD
Dr Landovitz has served on the scientific advisory board for Gilead Sciences, Inc. (Updated 05/05/22)
Susanna Naggie, MD
Dr Naggie has received research support from AbbVie, Gilead Sciences, Inc, and Pardes Biosciences and served as scientific advisor to Silverback
Therapeutics and Vir Biotechnology. (Updated 02/19/23)
Michael S. Saag, MD
Dr Saag has received research grants and support awarded to his institution from Gilead Sciences, Inc and ViiV Healthcare. (Updated 04/20/22)
Robert T. Schooley, MD
Dr Schooley has served as a consultant to CytoDyn and has receives royalties from Antiva Biosciences and CytoDyn. He serves on the board for Gilead Sciences, Inc., with payment remitted to his institution. He serves on the data and safety monitoring boards for Gilead Sciences, Inc., and VIR with payment remitted to his institution. His spouse serves on a data and safety monitoring board for GlaxoSmithKline/ViiV Healthcare and has received research grants awarded to her institution from Gilead Sciences, Inc. (Updated 04/20/22)